Important Safety Information
- FOSRENOL is contraindicated in patients with bowel obstruction, ileus, and fecal impaction.
- Serious cases of gastrointestinal obstruction, ileus, subileus, gastrointestinal perforation, and fecal impaction have been reported in patients taking lanthanum, some requiring surgery or hospitalization. Risk factors for gastrointestinal obstruction and perforation include altered gastrointestinal anatomy, hypomotility disorders, and concomitant medications.
- Instruct patients to chew or crush the tablet completely to reduce the risk of serious adverse gastrointestinal events. Patients with poor dentition, or those who have difficulty chewing tablets may be prescribed the oral powder or advised to crush the tablet completely. Advise patients to take FOSRENOL with or immediately after meals.
- Patients with acute peptic ulcer, ulcerative colitis, Crohn’s disease, or bowel obstruction were not included in FOSRENOL clinical studies.
- FOSRENOL has radio-opaque properties and may give the appearance typical of an imaging agent during abdominal X-ray procedures.
- The most common adverse reactions seen with FOSRENOL in clinical trials included nausea, vomiting, diarrhea, and abdominal pain.
There is potential for FOSRENOL to interact with:
These concomitant medications should be dosed separately from FOSRENOL to avoid drug interactions. See the Full Prescribing Information for dosing recommendations.
||compounds that bind to cationic antacids (i.e., aluminum-, magnesium-, or calcium-based)
||oral quinolone antibiotics
||thyroid hormone replacement therapy
- FOSRENOL is Pregnancy Category C. FOSRENOL is not recommended for use during pregnancy. It is not known whether FOSRENOL is excreted in human milk. Use caution when prescribing FOSRENOL to a nursing woman.
- The safety and efficacy of FOSRENOL in pediatric patients have not been established. The use of FOSRENOL in this population is not recommended.
FOSRENOL is indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).
Please click here for Full Prescribing Information.
Thank you for registering!
You have been removed from our mailing list.